|
Glioblastoma
|
|
|
|
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K,
Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker
D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S,
Mischel PS, Mellinghoff IK, Sawyers CL
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with
Recurrent PTEN-Deficient Glioblastoma
PLoS Med. 2008 Jan 22;5(1):e8. [Epub ahead of print]
Abstract
| 
Full Text |
Reprint |
DBLinks | BL 7:3
|
|
A. Das, M. Badruddoja,
D. Tryciecky, J. Yu and K. Black
Phase I study of gefitinib and rapamycin
in patients with recurrent or progressive glioblastoma (Gbm)
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1572
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement),
2005: 1572
|
|
|
|
Gliomas
|
|
|
Amy B.
Heimberger, Enze Wang, Eric C. McGary, Kenneth R. Hess, Verlene K.
Henry, Tadahisa Shono, Zvi Cohen, Joy Gumin, Raymond Sawaya, Charles A.
Conrad, and Frederick F. Lang
Mechanisms of action of
rapamycin in gliomas
Neuro-Oncology, Volume 7,
Number 1, Pages 1--11, January 2005. (Abstract+)
|
|
|
| Tumors
|
|
|
Guba
M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ,
Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK
Rapamycin inhibits primary and metastatic tumor growth
by antiangiogenesis: involvement of vascular endothelial growth factor
Nat Med 2002 Feb;8(2):128-35
|
|
|
Thuy
L. Phung,
Keren Ziv,
Donnette Dabydeen,
Godfred Eyiah-Mensah,
Marcela Riveros,
Carole Perruzzi,
Jingfang Sun,
Rita A. Monahan-Earley,
Ichiro Shiojima,
Janice A. Nagy, Michelle
I. Lin,
Kenneth Walsh,
Ann M. Dvorak,
David M. Briscoe, Michal Neeman,
William C. Sessa,
Harold F. Dvorak,
and Laura
E. Benjamin
Pathological
angiogenesis is induced by sustained Akt signaling and inhibited by
rapamycin
Cancer Cell, Vol 10, 159-170, August 2006.
Published: August 14, 2006.
|
|
|
|
